Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 2/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900391 | 0.85 | CYP17A1 (0.74) | CYP17A1CYP1A2 | |
| SCHEMBL900217 | 0.85 | CYP17A1 (0.74) | CYP17A1CYP1A2METAP2 | |
| SCHEMBL900104 | 0.82 | CYP17A1 (1.00) | CYP17A1CYP1A2METAP2 | |
| SCHEMBL903225 | 0.82 | CYP17A1 (0.70) | CYP17A1CYP1A2 | |
| SCHEMBL900497 | 0.78 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL903217 | 0.78 | CYP17A1 (1.00) | CYP17A1CYP1A2METAP2 | |
| SCHEMBL900219 | 0.76 | CYP17A1 (0.71) | CYP17A1CYP1A2KDM4E | |
| SCHEMBL30119632 | 0.76 | CYP17A1 (0.60) | CYP17A1CYP1A2ADORA2AADORA1 | |
| SCHEMBL900105 | 0.75 | CYP17A1 (0.73) | CYP17A1CYP1A2 | |
| SCHEMBL900411 | 0.74 | CYP17A1 (0.71) | CYP17A1CYP1A2PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | claimed |
| EP-2621913-B1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | claimed |
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-21 | — | — | US | claimed |
| EP-2621913-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012044537-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2621913-B1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2621913-B1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2621913-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044537-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044537-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | CYP3A43, CYP2C18, CYP3A7 | CYP17A1 40/4885CYP1A2 12/4885DGAT1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.